Who owns CRISPR-Cas9 in Europe?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 25489834.
- Also identified by DOI 10.1038/nbt.3086.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.
Medical subject headings
- CRISPR-Cas Systems
- Intellectual Property